RxDoctor Payments Data

Dusan Knezevic, MD

Cardiovascular Disease · Glen Ridge, NJNPI 1023062866

Payments from drug & device makers

$1,810in general payments, 2019–2025

Across 110 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$472
  • Amgen$391
  • Johnson & Johnson$129
  • E.r. Squibb & Sons, L.L.C.$117
  • AstraZeneca$112
  • Pfizer$90
  • plus $498 from 17 others

What the payments were for

  • Food & beverage$1,69894%
  • Education$1116%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,810 in reported general payments places this provider in the 35th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$323,519
Medicare patients
1,741
Services billed
3,927

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban828$925,639
XareltoRivaroxaban137$167,982
JardianceEmpagliflozin67$100,906
EntrestoSacubitril/Valsartan64$85,982
Repatha SureclickEvolocumab79$64,711
Praluent PenAlirocumab37$24,784
MultaqDronedarone Hcl21$20,146
Repatha SyringeEvolocumab21$18,594
BrilintaTicagrelor20$13,983
Metoprolol Succinate692$10,826
Atorvastatin Calcium887$10,122
Diltiazem 24hr Er (Cd)Diltiazem Hcl178$9,108
Rosuvastatin Calcium419$6,673
Amlodipine Besylate604$5,289
Ezetimibe117$5,083

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$90$925,639828 claims
Johnson & JohnsonXarelto$129$167,982137 claims
Boehringer IngelheimJardiance, Pradaxa$16$103,61481 claims
NovartisEntresto$472$85,98264 claims
Sanofi-aventis U.S. LLCMultaq$13$20,14621 claims
AstraZenecaBrilinta$112$13,98320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Glen Ridge

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →